Marker Therapeutics (MRKR) Enterprise Value (2010 - 2026)

Marker Therapeutics (MRKR) has reported Enterprise Value for 17 consecutive years, with $12.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Enterprise Value rose 209.72% year-over-year to $12.6 million in Q2 2026; TTM through Jun 2026 was $12.6 million, a 209.72% increase from a year earlier, with the FY2025 full-year figure at $7.8 million, down 44.51% from the prior year.
• Enterprise Value was $12.6 million for Q2 2026 at Marker Therapeutics, up from $6.1 million in the prior quarter.
• Over five years, Enterprise Value peaked at $40.5 million in Q2 2024 and troughed at -$4.1 million in Q3 2025.
• A 5-year average of $12.4 million and a median of $10.0 million in 2022 frame the typical range for Enterprise Value.
• Across the five-year window, Enterprise Value surged 17684.19% in 2024 and slumped 125.64% in 2025, its largest moves.
• Over 5 years, Enterprise Value stood at $10.9 million in 2022, then jumped by 210.51% to $33.8 million in 2023, then slumped by 58.38% to $14.1 million in 2024, then slumped by 44.51% to $7.8 million in 2025, then soared by 61.46% to $12.6 million in 2026.
• The last three Enterprise Value figures came in at $12.6 million (Q2 2026), $6.1 million (Q1 2026), and $7.8 million (Q4 2025), per Business Quant data.